Zai Lab Ltd
$ 18.20
0.61%
06 Jan - close price
- Market Cap 2,004,129,000 USD
- Current Price $ 18.20
- High / Low $ 18.97 / 18.14
- Stock P/E N/A
- Book Value 6.87
- EPS -1.90
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.29 %
- 52 Week High 44.34
- 52 Week Low 16.82
About
Zai Lab Limited (ZLAB), based in Shanghai, China, is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of cutting-edge therapies targeting cancer, autoimmune diseases, and infectious diseases. With a robust pipeline of innovative drug candidates, Zai Lab strategically collaborates with global partners to meet critical unmet medical needs. As the biopharmaceutical landscape evolves, the company remains focused on improving patient outcomes through impactful research and development efforts, solidifying its role as a key player in the industry.
Analyst Target Price
$49.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-03-01 |
| Reported EPS | -0.33 | -0.04 | -0.45 | -0.8 | -0.42 | -0.8 | -0.5 | -1 | -0.71 | -1.25 | -0.51 | -0.65 |
| Estimated EPS | -0.2453 | -0.41 | -0.5475 | -0.6333 | -0.78 | -0.71 | -0.92 | -0.86 | -1.04 | -0.79 | -0.95 | -1.11 |
| Surprise | -0.0847 | 0.37 | 0.0975 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.14 | 0.33 | -0.46 | 0.44 | 0.46 |
| Surprise Percentage | -34.5291% | 90.2439% | 17.8082% | -26.3224% | 46.1538% | -12.6761% | 45.6522% | -16.2791% | 31.7308% | -58.2278% | 46.3158% | 41.4414% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.38 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-01-07 11:10:35
Zai Lab has secured NMPA approval in China for its drug Augtyro (repotrectinib) to treat adult patients with NTRK gene fusion-positive solid tumors. This marks Augtyro's second indication in China, addressing a significant unmet medical need for patients who have progressed on prior therapies or lack satisfactory alternatives. The approval was based on results from the pivotal Phase I/II TRIDENT-1 study, which demonstrated the drug's durable efficacy and manageable safety profile.
2026-01-07 07:10:35
UBS initiated coverage on Zai Lab (NASDAQ:ZLAB) with a Buy rating and a $35 price target, citing the company's evolution from a China-focused model to a global innovation leader. Despite recent commercial setbacks and past earnings misses, UBS views Zai Lab as an undervalued biopharma platform with a strong global pipeline, offering significant long-term growth potential. The firm believes the market currently undervalues the company's strategic positioning and diversified revenue streams.
2026-01-06 14:10:35
Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has approved AUGTYRO™ (repotrectinib) for adult patients with NTRK gene fusion-positive solid tumors. This marks the drug's second indication in China, addressing a significant unmet medical need for both TKI-naïve and TKI-pretreated patients. The approval is based on the robust results from the pivotal Phase 1/2 TRIDENT-1 study, demonstrating durable efficacy and a manageable safety profile.
2026-01-06 12:09:06
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) announced that China's National Medical Products Administration (NMPA) has approved AUGTYRO™ (repotrectinib) for adult patients with NTRK-positive solid tumors. This marks AUGTYRO's second indication in China, addressing a significant unmet medical need for patients with locally advanced or metastatic solid tumors who have progressed on prior therapies or have no satisfactory alternative treatment options. The approval is based on the robust efficacy and manageable safety profile demonstrated in the pivotal Phase 1/2 TRIDENT-1 study.
2026-01-06 06:09:06
Zai Lab (ZLAB) has experienced recent stock volatility, including a 4.4% gain yesterday but a 46.3% decline over the past three months. Despite long-term pressure, analysts and intrinsic estimates suggest the stock is significantly undervalued, with a fair value around US$49.49 compared to its current price of US$18.09. However, market ratios indicate mixed signals, and key risks include reliance on in-licensed assets and intense competition in oncology markets.
2026-01-05 14:26:37
Zai Lab Limited announced that its senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PST / 6:00 p.m. EST. A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s website, with an archived replay accessible for 30 days. Zai Lab focuses on discovering, developing, and commercializing innovative biopharmaceutical products for unmet medical needs in oncology, immunology, neuroscience, and infectious disease.
